Cover Image
市場調查報告書

P2X嘌呤受體7:開發中產品分析

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 365739
出版日期 內容資訊 英文 39 Pages
訂單完成後即時交付
價格
Back to Top
P2X嘌呤受體7:開發中產品分析 P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H2 2017
出版日期: 2017年07月25日 內容資訊: 英文 39 Pages
簡介

本報告提供以P2X嘌呤受體7為標的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

P2X嘌呤受體7 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 開發中的產品:各企業

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Affectis Pharmaceuticals AG
  • Axxam SpA
  • Biosceptre (Aust) Pty Ltd
  • Evotec AG
  • Johnson & Johnson
  • Medestea Research & Production S.p.A.

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0954TDB

Summary:

According to the recently published report 'P2X Purinoceptor 7 - Pipeline Review, H2 2017'; P2X Purinoceptor 7 (P2Z Receptor or P2RX7) pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies.

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - P2X purinoceptor 7 is a protein encoded by the P2RX7 gene. It acts as receptor for ATP that acts as a ligand-gated ion channel. It is responsible for ATP-dependent lysis of macrophages through the formation of membrane pores permeable to large molecules.

The report 'P2X Purinoceptor 7 - Pipeline Review, H2 2017' outlays comprehensive information on the P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 5 and 1 respectively. Report covers products from therapy areas Central Nervous System, Immunology, Oncology, Gastrointestinal, Genetic Disorders, Metabolic Disorders and Musculoskeletal Disorders which include indications Neuropathic Pain, Inflammation, Multiple Sclerosis, Alzheimer's Disease, Autoimmune Disorders, Basal Cell Carcinoma (Basal Cell Epithelioma), Bipolar Disorder (Manic Depression), Charcot-Marie-Tooth Disease Type I A, Depression, Inflammatory Bowel Disease, Major Depressive Disorder, Mania, Muscular Dystrophy, Neurodegenerative Diseases, Osteoarthritis Pain, Psoriasis, Rheumatoid Arthritis, Solid Tumor, Systemic Lupus Erythematosus, Transplant Rejection, Type 1 Diabetes (Juvenile Diabetes) and Visceral Pain.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for P2X Purinoceptor 7 (P2Z Receptor or P2RX7)
  • The report reviews P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics and enlists all their major and minor projects
  • The report assesses P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for P2X Purinoceptor 7 (P2Z Receptor or P2RX7)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding P2X Purinoceptor 7 (P2Z Receptor or P2RX7) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Overview
    • P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Companies Involved in Therapeutics Development
    • Affectis Pharmaceuticals AG
    • Axxam SpA
    • Biosceptre International Ltd
    • Evotec AG
    • Johnson & Johnson
    • Medestea Research & Production SpA
  • P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Drug Profiles
    • AFC-5128 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BIL-010t - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BIL-06v - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EVT-401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-47965567 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-5446 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize P2X7 Receptor for Central Nervous System - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize P2RX7 for CNS Disorders, Autoimmune Disorders and Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • WITH-1101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Dormant Products
  • P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Discontinued Products
  • P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Product Development Milestones
    • Featured News & Press Releases
      • Mar 03, 2017: Biosceptre publishes a clinical study of topical drug BIL010t as therapy for Basal cell carcinoma
      • Dec 18, 2014: Alzheimer's Drug Discovery Foundation And Axxam Continue Their Successful Collaboration To Develop Novel Therapeutics For Alzheimer's Disease
      • Jul 22, 2014: Biosceptre Announces Positive Phase I Results for BIL-010t to Treat Basal Cell Carcinoma
      • Jan 25, 2012: Affectis Receives European Patent For AFC-5128 And Other P2X7 Antagonists
      • Jun 29, 2009: Evotec Announces The Successful Completion Of The First Phase I Study With EVT 401
      • Oct 09, 2008: Evotec Announces Phase I Initiation With P2X7 Antagonist
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Affectis Pharmaceuticals AG, H2 2017
  • Pipeline by Axxam SpA, H2 2017
  • Pipeline by Biosceptre International Ltd, H2 2017
  • Pipeline by Evotec AG, H2 2017
  • Pipeline by Johnson & Johnson, H2 2017
  • Pipeline by Medestea Research & Production SpA, H2 2017
  • Dormant Projects, H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top